New Pharma Commerce column addresses the relevance of pricing.
Ed Schoonveld
Advertisement
Articles by Ed Schoonveld
Exploring the legislation's diverging requirements between regulatory agencies and global payers, and its impact on the commercial results of biopharma companies
Shared-risk or ‘pay for performance’ agreements between drugmakers and payers can represent uncertain rewards for both parties. Use strategic planning before entering into them
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
The Hidden Architecture of Drug Shortages: Why Inventory Economics Determine Patient Access
2
How China Turned US Trade Compliance Into a Supply Chain Risk
3
Gerren McHam: What Effective Pharma Reshoring Actually Requires
4
GEODIS Thermal Covers Mark Step Toward Sustainable Pharma Airfreight Packaging
5